Novo Nordisk has experienced a notable decline in its stock price, dropping by 12.08% over the past week. This downturn comes amid increased competition in the weight loss and dia ...

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced. The Food and ...

Allied Market Research published a report titled, "HealthTech Market - Global Opportunity Analysis and Industry Forecast, 2024-2033," valued ...

Novo Nordisk (NVO) said it has become aware of several hundred units of Ozempic injection outside the Novo Nordisk authorized supply chain in ...

Healthcare stocks ended a volatile Wall Street week on a positive note. Explore top movers, Novartis' $23B U.S.

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

A regional health meeting held this week in Dar es Salaam brought together experts, health officials, and patient ...

Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs by 2028 in Montes Claros.

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil. | Looking to ...